US FDA approves radium-223 dichloride for treatment of men with mCRPC

Posted on May 16, 2013 by Sitemaster

The “New” Prostate Cancer InfoLink apologizes for a delay in letting readers know that on Wednesday the US Food & Drug Administration approved radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, but no known visceral (i.e., soft tissue) metastases. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: , , , , | Leave a Comment »

Ipilimumab ± radiation therapy in men with mCRPC

Posted on May 8, 2013 by Sitemaster

Final data have just been reported on the results of a Phase I/II study of treatment with ipilimumab as monotherapy and in combination with radiotherapy in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE ..

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , | Leave a Comment »

Overall survival and rPFS data from the PREVAIL trial expected later this year

Posted on April 1, 2013 by Sitemaster

According to a media release issued by Astellas Pharma and Medivation, the companies now expect to conduct an interim analysis of the PREVAIL trial of enzalutamide (a.k.a. MDV3100 or Xtandi) for overall survival some time later this year. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | Leave a Comment »

CureVac starts Phase IIb trial of CV9104

Posted on March 27, 2013 by Sitemaster

A German company called CureVac GmbH has started Phase IIb clinical trials of another cancer “vaccine” for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: , , , , , , | 2 Comments »

More on docetaxel given every 2 weeks

Posted on January 15, 2013 by Sitemaster

A few days ago we reported on a paper by a Finnish research team who had compared treatment of men with mCRPC with docetaxel given every 2 weeks as opposed to the standard therapy of every 3 weeks. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | Leave a Comment »

Abiraterone acetate in chemotherapy-naive mCRPC: full data published

Posted on January 10, 2013 by Sitemaster

An article published this week in the New England Journal of Medicine gives the full results of the Phase III trial of abiraterone acetate + prednisone in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). These data were originally reported at the ASCO annual meeting in 2011. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 6 Comments »

Phase III trial of tasquinimod in mCRPC also now fully enrolled

Posted on January 3, 2013 by Sitemaster

According to a December 10 media release issued by Active Biotech and Ipsen, the pivotal Phase III trial of tasquinimod versus a placebo in the treatment of men with asymptomatic to mildly symptomatic, metastatic, castration-resistant prostate cancer (mCRPC) is also now fully enrolled. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , | Leave a Comment »

Data from MAINSAIL trial provides us with a cautionary tale

Posted on January 2, 2013 by Sitemaster

In November 2011 we reported that Celgene had terminated the Phase III, MAINSAIL trial of lenalidomide (Revlimid®) in combination with docetaxel and prednisone in treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) for lack of efficacy. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | Leave a Comment »

Data from trial of abiraterone in chemo-naive mCRPC published in NEJM

Posted on December 13, 2012 by Sitemaster

This week’s issue of the New England Journal of Medicine (NEJM) carries the full report of the results of the so-called COU-AA-302 trial of abiraterone + prednisone vs. a placebo + prednisone in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 7 Comments »

Bayer submits application for approval of radium-223 in Europe

Posted on December 12, 2012 by Sitemaster

Based on data from the randomized, Phase III ALSYMPCA trial, Bayer has today submitted a Marketing Authorization Application to the European Medicines Agency for radium-223 dichloride in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC).

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | Leave a Comment »

FDA approves abiraterone acetate for chemotherapy-naive mCRPC

Posted on December 10, 2012 by Sitemaster

According to an announcement earlier today, the U. S. Food and Drug Administration (FDA) has approved an expanded indication for abiraterone acetate (Zytiga®) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), inclusive of patients who have not received any form of chemotherapy. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 12 Comments »

Four major advances in treatment of late stage prostate cancer in 2012

Posted on December 5, 2012 by Sitemaster

In a new paper in the Journal of Clinical Oncology, the American Society for Clinical Oncology (ASCO) has identified four significant advances in the treatment of late stage prostate cancer during 2012. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , , | 5 Comments »

Provenge + CT-011 + cyclophosphamide in treatment of mCRPC

Posted on December 5, 2012 by Sitemaster

The Georgia Health Sciences University in Augusta, GA, has initiated a new trial of sipuleucel-T (Provenge) in combination with cyclophosphamide and an investigational drug known as CT-011 for the treatment of chemotherapy-naive patients with progressive, metastatic, castrate-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | Leave a Comment »

AEZS 108 enters Phase II clinical trial in men with taxane-refractory mCRPC

Posted on November 12, 2012 by Sitemaster

According to a company media release, Aeterna Zentaris has initiated the Phase II component of the Phase I/II trial of AEZS 108 in the treatment of men with castration- and taxane-resistant prostate cancer. … READ MORE …

Filed under: Drugs in development, Management | Tagged: , , , | Leave a Comment »

PSMA-ADC shows positive results in Phase I clinical trial in advanced mCRPC

Posted on November 8, 2012 by Sitemaster

According to data presented today at the Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, a new type of targeted drug therapy has shown early positive results in men with metastatic, castration-resistant porstate cancer (mCRPC) who had also failed at least two forms of chemotherapy. … READ MORE …

Filed under: Drugs in development | Tagged: , , , , | Leave a Comment »

Next Page »
Follow

Get every new post delivered to your Inbox.

Join 832 other followers